NeuroAid II (MLC901) in Haemorrhagic Stroke [PDF]
Case Reports in Neurology, 2020 Stroke is a leading cause of death and disability. NeuroAid (MLC601), which originates from Traditional Chinese Medicine, comprises herbal and animal components, and has been shown to improve the functional status of patients after ischaemic stroke.
Chai-Hoon Nowel Tan +2 more
doaj +5 more sources
NEURoaid II (MLC901) in cognitively Impaired not demenTEd patientS (NEURITES): A pilot double blind, placebo‐controlled randomized trial [PDF]
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2021 Objective To investigate the efficacy and safety of MLC901 in vascular cognitive impairment no dementia (VCIND) patients. Design This was a multi‐center, double‐blind, randomized, placebo‐controlled pilot study.
Christopher L. H. Chen +8 more
doaj +4 more sources
Systematic Review and Meta-Analysis of the Efficacy of MLC901 (NeuroAiD II) for Acute Ischemic Brain Injury in Animal Models [PDF]
Journal of Evidence-Based Integrative Medicine, 2021 Introduction. Moleac (MLC) 901 is a traditional Chinese medication approved by the Sino Food and Drug Administration in 2001 for treating stroke. This study aims to analyze the efficacy of MLC901 in animal stroke models after medial cerebral artery ...
I. G. M. Aswin R. Ranuh MD +4 more
doaj +6 more sources
The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild‐to‐moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double‐blind, placebo‐controlled trial [PDF]
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2019 Background Dementia is a large and growing health care burden globally, and its major cause is Alzheimer's disease (AD). MLC901 (Neuroaid II) is a simplified form of MLC601 (Neuroaid), a Traditional Chinese Medicine with neuroprotective and ...
Christopher L.H. Chen +4 more
doaj +5 more sources
NeuroAiDTM-II (MLC901) Promoted Neurogenesis by Activating the PI3K/AKT/GSK-3β Signaling Pathway in Rat Spinal Cord Injury Models [PDF]
BiomedicinesTraumatic damage to the spinal cord (SCI) frequently leads to irreversible neurological deficits, which may be related to apoptotic neurodegeneration in nerve tissue. The MLC901 treatment possesses neuroprotective and neuroregenerative activity.
Anam Anjum +8 more
doaj +4 more sources
NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report [PDF]
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021 Background NeuroAid II (MLC901) is a promising therapy for stroke patients who present outside of therapeutic window for reperfusion therapy. Studies have proven its efficacy in ischemic stroke; however, data of drug safety and combination with other ...
Anna Misya’il Abdul Rashid +10 more
doaj +2 more sources
Antiepileptic Effect of Neuroaid® on Strychnine-Induced Convulsions in Mice [PDF]
Pharmaceuticals, 2022 NeuroAid II, a folk Chinese Medicine, is currently used in Asia for the treatment of stroke. An experimental study demonstrated that NeuroAid enables neuronal cells to be more resistant to glutamate toxicity. This research was constructed to evaluate the
Ahmed Salim Mahmood +7 more
doaj +2 more sources
Randomised, double-blind, placebo-controlled study investigating Safety and efficAcy of MLC901 in post-traUmatic bRAin Injury: the SAMURAI study protocol [PDF]
BMJ Open, 2022 Introduction Traumatic brain injury (TBI) is a leading cause of death in young adults globally and 90% of cases are mild TBI. Treatment to facilitate recovery after TBI is needed.
Marek Majdan +6 more
doaj +2 more sources
MLC901 (NeuroAiD II™) for cognition after traumatic brain injury: a pilot randomized clinical trial. [PDF]
Eur J Neurol, 2018 Background and purposeTreatments to facilitate recovery after traumatic brain injury (TBI) are urgently needed. We conducted a 9‐month pilot, randomized placebo‐controlled clinical trial to examine the safety and potential effects of the herbal supplement MLC901 (NeuroAiD II™) on cognitive functioning following TBI.MethodsAdults aged 18–65 years at 1 ...
Theadom A +5 more
europepmc +4 more sources
Integrative molecular simulations reveal NeuroAid II mechanisms in ischemic stroke through network pharmacology, molecular dynamics, and pharmacophore modeling [PDF]
Scientific ReportsIschemic stroke remains a major health challenge with limited treatment options. NeuroAid II (MLC901), a multi-herbal remedy, has shown clinical promise in post-stroke recovery, though its molecular mechanisms are unclear.
Doni Dermawan +4 more
doaj +2 more sources